Skip to Content

Ifosfamide Dosage

Medically reviewed on October 22, 2018.

Applies to the following strengths: 1 g; 3 g; 50 mg/mL

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Testicular Cancer

For third line chemotherapy of germ cell testicular cancer:

1.2 g/m2, diluted to 50 mg/mL IV over 30 minutes once a day with mesna (intravenous, oral, or continuous intravenous infusion) just before and 4 and 8 hours after each dose and aggressive (usually IV) hydration (2 to 4 L/day).

Ifosfamide is usually given for 5 days, with 5 day regimens repeated every 3 to 4 weeks, and after recovery from hematologic toxicity.

Usual Adult Dose for Cervical Cancer

(In combination with other chemotherapeutic agents as a part of the BIP regimen)
5,000 mg/m2 IV over 24 hours on day 2
Cycle repeated every 21 days

(In combination with other chemotherapeutic agents as a part of the BIC regimen)
2,000 mg/m2 IV on days 1 through 3
Cycle repeated every 21 days

Usual Pediatric Dose for Malignant Disease

1200 to 1800 mg/m2/day for 3 to 5 days every 21 to 28 days


5000 mg/m2 as a single 24 hour infusion


3 g/m2/day for 2 days

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

The recommended dose of ifosfamide may depend on whether other cytotoxic agents are coadministered. For adults, many experts recommend total daily doses as high as 5 g/m2 or total doses over 4 days of 8 to 18 g/m2. Reference to specific protocols is recommended.


-MYELOSUPPRESSION: This adverse event can be severe and lead to fatal infections. Monitor blood counts prior to and at intervals after each treatment cycle.
-CENTRAL NERVOUS SYSTEM (CNS) TOXICITIES: These toxicities can be severe and result in encephalopathy and death. Monitor for CNS toxicity and discontinue treatment if encephalopathy occurs.
-NEPHROTOXICITY: This toxicity can be severe and result in renal failure.
-HEMORRHAGIC CYSTITIS: This adverse event can be severe and can be reduced by the prophylactic use of mesna.

Consult WARNINGS section for additional precautions.

Use with caution in patients with renal or hepatic impairment. Unless clinically essential, initial or repeat doses should not be given to patients with a white blood cell count less than 1500 to 2000/mm3 and/or a platelet count less than 50,000/mm3. Because of the common occurrence of hemorrhagic cystitis associated with the use of ifosfamide, checking the urine for blood (dipstick) or urinalysis prior to each dose, vigorous hydration and monitoring for adequate urine output, frequent bladder voiding, concomitant use of a prophylactic agent (such as mesna, 2-mercaptoetjene sulfonate), and close monitoring of serum and urine chemistries (including phosphorus, potassium, and alkaline phosphatase) are strongly recommended. Ifosfamide should be discontinued if neurologic symptoms of somnolence, irritability, anxiety, confusion, hallucinations, or coma are observed.


Data not available

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.